Pfizer raises revenue guidance by $1.5B amid activist pressure
Pfizer hasn’t escaped the volatility of its Covid-19 business — for better or worse. Making its first substantive comments on the activist investor pushing for changes at the company, Pfizer on Tuesday...
View ArticleParagon launches another company in hot PD-1xVEGF space that goes straight to...
Antibody maker Paragon Therapeutics has formed another company, this time in the bustling cancer space of PD-1xVEGF, and it will go straight onto the public markets. The new biotech, named Crescent...
View ArticlePathos AI nabs $62M Series C as it hunts for more Phase 1 drugs with AI
Chicago startup Pathos AI has completed a $62 million Series C to keep looking for Phase 1 cancer drugs that it can acquire and test in more specific patient populations, it
View ArticleGLP-1 compounding pharmacies took center stage at digital health’s biggest...
LAS VEGAS — The hottest companies at this year's annual HLTH conference weren't buzzy startups with billions in backing for a new approach to disrupt the healthcare industry. They were compounding...
View ArticleEyepoint sells $100M in shares after unveiling eye disease data for...
EyePoint Pharmaceuticals is selling $100 million worth of shares on the back of positive mid-stage data for a drug-device candidate in diabetic macular edema. The results pushed its share price up by...
View ArticleGSK buys autoimmune T cell engager for $300M upfront from Chimagen
As early data show how T cell engagers — originally developed for cancers — can potentially treat a range of autoimmune diseases, GSK is buying its own molecule from Chimagen Biosciences. The UK pharma...
View ArticleTwo type 1 diabetes patients are insulin-free after Eledon's...
Eledon Pharmaceuticals’ experimental immunosuppressant helped two patients with type 1 diabetes go insulin-free following an islet cell transplant, the company announced Tuesday. The company's stock...
View ArticleVera’s $300M offering; Abeona resubmits treatment for rare skin disease
Plus, news about Astellas, Clover, ElevateBio, Monopar, Idorsia and Neurocrine Biosciences: Vera Therapeutics plans $300M offering: The California biotech is selling shares after presenting Phase 2b...
View ArticleIn bid to lower ARIA-E, Eli Lilly tries a different dosing regimen for its...
Eli Lilly presented new data illustrating how a different dosing regimen of its Alzheimer’s drug reduced the frequency of brain swelling. The results could help Lilly argue for a change to Kisunla’s...
View ArticleNovartis highlights overall M&A track record following MorphoSys impairment
Novartis CEO Vas Narasimhan assured investors on Tuesday that it takes a careful, systematic approach to M&A after recording an $800 million impairment to its recent MorphoSys acquisition. During...
View ArticlePacBio bets on 'inflection point' with $500 long-read genome
Pacific Biosciences says it can produce high-fidelity genetic code for as little as $500, a move that aims to reach more labs and revive the company's struggling business. The company on Tuesday...
View ArticleMilliporeSigma invests €70M to triple ADC manufacturing at US site
Merck KGaA, through its life science arm MilliporeSigma, is again increasing its manufacturing footprint for ADCs, this time by allocating €70 million ($75.6 million) to expand production in North...
View ArticleShionogi touts topline data for Covid-19 antiviral for post-exposure treatment
Shionogi’s once-daily 3CL protease inhibitor hit on a primary endpoint in a late-stage trial as a post-exposure prophylaxis treatment for Covid-19 after failing a Phase 3 study in May. The oral...
View ArticleNovartis expands Scemblix label to first-line CML patients
Novartis’ chronic myeloid leukemia drug Scemblix will now be available to newly diagnosed patients, the FDA announced on Tuesday. Scemblix was first approved in 2021 for use as a third-line treatment....
View ArticleCoya shares sink on Phase 2 Alzheimer's data for deprioritized drug
Coya Therapeutics’ stock price {$COYA} fell more than 20% on Tuesday after the company reported Phase 2 data for its Alzheimer’s disease program, called COYA 301. Though Coya de-emphasized COYA 301 as...
View ArticleFDA again questions Lexicon diabetes drug ahead of adcomm
The FDA is raising repeat safety and efficacy questions ahead of an advisory committee meeting on Thursday for Lexicon Pharmaceuticals' SGLT2 inhibitor sotagliflozin, which the agency rejected in 2019...
View ArticleWhat would RFK Jr. do on healthcare? Trump ally's FDA plans raise alarm
Donald Trump's embrace of Robert F. Kennedy Jr. is forcing biotech and pharma leaders to grapple with having US life sciences policy influenced by a figure who has extensively criticized vaccines and...
View ArticleFollowing March inspection, Novo Nordisk's semaglutide manufacturing facility...
The FDA on Tuesday released an inspection report sent to Novo Nordisk earlier this year citing quality-related issues at a site in Kalundborg, Denmark, that manufactures its blockbuster semaglutide...
View ArticlePfizer shares new details on obesity pipeline, hints at ‘other opportunities’
As Pfizer talked up the strength of its pipeline Tuesday, it shared details for the first time about its plans in obesity and said it has a multi-pronged strategy to catch up to rivals in ...
View ArticleZurzuvae won't be developed for major depression, Sage says
It’s official: Sage and Biogen will not attempt to get their postpartum depression pill Zurzuvae approved in the broader population of people with major depressive disorder. Sage, which has recently...
View Article